(Albany, US) DelveInsight has launched a new report on Neuromyelitis Optica Market Insights, Epidemiology and Market Forecast-2030
"Neuromyelitis Optica Pipeline Insight, 2020" report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects across the Neuromyelitis Optica market. A detailed picture of the Neuromyelitis Optica pipeline landscape is provided, which includes the disease overview and Neuromyelitis Optica treatment guidelines. The assessment part of the report embraces in-depth Neuromyelitis Optica commercial assessment and clinical assessment of the Neuromyelitis Optica pipeline products from the pre-clinical developmental phase to the marketed phase. In the report, a detailed description of the drug is proffered including mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Neuromyelitis Optica collaborations, licensing, mergers and acquisition, funding, designations, and other product-related details.
The characteristic symptoms of NMOSD are either optic neuritis or myelitis; either may occur as the first symptom. Optic neuritis is inflammation, of the optic nerve (optic neuritis) leading to pain inside the eye which rapidly is followed by loss of clear vision (acuity). Usually, only one eye is affected (unilateral) although both eyes may be involved simultaneously (bilateral). NMOSD may or may not be preceded by a prodromal upper respiratory infection.
Request for :- NMOSD free sample page
Neuromyelitis Optica of pipeline development activities
The report provides insights into:
- All of the companies that are developing therapies for the treatment of Neuromyelitis Optica with aggregate therapies developed by each company for the same.
- Different therapeutic candidates segmented into early-stage, mid-stage and late stage of development for the Neuromyelitis Optica treatment.
- Neuromyelitis Optica key players involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
- Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
- Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of Neuromyelitis Optica market.
The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university web sites and industry-specific third-party sources, etc.
Neuromyelitis Optica Analytical Perspective by DelveInsight
- In-depth Neuromyelitis Optica Commercial Assessment of products
This report provides a comprehensive commercial assessment of therapeutic drugs that have been included, which comprises of collaborations, licensing, and acquisition deal value trends. The report also covers company-company collaborations (licensing/partnering), company-academia collaborations, and acquisition analysis in both graphical and tabulated form in a detailed manner.
- Neuromyelitis Optica Clinical Assessment of products
The report comprises of comparative clinical assessment of products by development stage, product type, route of administration, molecule type, and MOA type across this indication.
Scope of the report
- The Neuromyelitis Optica report provides an overview of therapeutic pipeline activity and therapeutic assessment of the products by development stage, product type, route of administration, molecule type, and MOA type for Neuromyelitis Optica across the complete product development cycle, including all clinical and nonclinical stages.
- It comprises of detailed profiles of Neuromyelitis Optica therapeutic products with key coverage of developmental activities, including technology, collaborations, licensing, mergers and acquisition, funding, designations and other product-related details
- Detailed Neuromyelitis Optica research and development progress and trial details, results wherever available, are also included in the pipeline study.
- Coverage of dormant and discontinued pipeline projects along with the reasons if available across Neuromyelitis Optica.
Key companies working on NMOSD pipeline are given below:-
1. Roche Pharma Co.
2. Alexion Pharma
Name of drugs covered are given below:-
1. Satralizumab (SA237)
2. Soliris
1. Report Introduction
2. Neuromyelitis Optica
3. Neuromyelitis Optica Current Treatment Patterns
3.1. Neuromyelitis Optica Treatment Guidelines
4. Neuromyelitis Optica - DelveInsight's Analytical Perspective
4.1.2.3. Neuromyelitis Optica Acquisition Analysis
5. Therapeutic Assessment
6. Neuromyelitis Optica Late Stage Products (Phase-III)
7. Neuromyelitis Optica Mid Stage Products (Phase-II)
8. Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Neuromyelitis Optica Discontinued Products
13. Neuromyelitis Optica Product Profiles
14. Neuromyelitis Optica Key Companies
15. Neuromyelitis Optica Key Products
16. Dormant and Discontinued Products
16.1. Dormant Products
16.1.1. Reasons for being dormant
16.2. Discontinued Products
16.2.1. Reasons for the discontinuation
17. Neuromyelitis Optica Unmet Needs
18. Neuromyelitis Optica Future Perspectives
19. Neuromyelitis Optica Analyst Review
20. Appendix
21. Report Methodology
21.1. Secondary Research
21.2. Expert Panel Validation
Related Reports:-
2. Neuromyelitis Optica Spectrum Disorder (NMOSD) - Epidemiology Forecast to 2030
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email
Phone: +919650213330
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/
